Publications by authors named "Victor Manuel Villalobos"
Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
Salvador Fudio
,
Josep Tabernero
,
Vivek Subbiah
,
Sant P Chawla
,
Victor Moreno
,
Victor Manuel Villalobos
Cancer Chemother Pharmacol
January 2021
Purpose: This study assessed the effect of lurbinectedin, a highly selective inhibitor of oncogenic transcription, on the change from baseline in Fridericia's corrected QT interval (∆QTcF) and electrocardiography (ECG) morphological patterns, and lurbinectedin concentration-∆QTcF (C-∆QTcF) relationship, in patients with advanced solid tumors.
Methods: Patients with QTcF ≤ 500 ms, QRS < 110 ms, PR < 200 ms, and normal cardiac conduction and function received lurbinectedin 3.2 mg/m as a 1-h intravenous infusion every 3 weeks.
Article Synopsis
- Desmoid fibromatosis is a type of tumor linked to mutations in the WNT pathway, and a study was conducted to evaluate the oral gamma secretase inhibitor PF-03084014 for treatment.
- In a small cohort of seven patients, 71.4% achieved a partial response to the treatment, with most maintaining their response for extended periods even after stopping the medication.
- The study concluded that PF-03084014 is effective and well-tolerated, showing significant disease control, particularly at lower doses.